<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2352">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728698</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-COV-201</org_study_id>
    <nct_id>NCT04728698</nct_id>
  </id_info>
  <brief_title>Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress</brief_title>
  <official_title>Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorrento Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorrento Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized controlled, multicenter study to assess the safety and efficacy&#xD;
      of COVI-MSC in the setting of current standard of care (SOC) treatments for COVID-19&#xD;
      infection in hospitalized subjects with ARD/ARDS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality at Day 28</measure>
    <time_frame>Randomization through Day 28</time_frame>
    <description>All-cause mortality at Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at Days 60 and 90</measure>
    <time_frame>Randomization through Day 60 and Day 90</time_frame>
    <description>All-cause mortality at Days 60 and 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilator-free days</measure>
    <time_frame>Randomization through Day 28</time_frame>
    <description>Number of ventilator-free days through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in oxygenation</measure>
    <time_frame>Randomization to Day 2, Day 4, Day 6, Day 14, Day 28</time_frame>
    <description>Improvement in oxygenation at Day 2, 4, 6, 14, and 28 compared to Baseline, as assessed by PaO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score at Day 28</measure>
    <time_frame>Randomization to Day 28</time_frame>
    <description>SOFA score at Day 28 compared to Baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>COVI-MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Excipient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COVI-MSC</intervention_name>
    <description>1 x 10^6 MSCs/kg or 1.5 x 10^6 MSCs/kg, depending on CRP level</description>
    <arm_group_label>COVI-MSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Equivalent volume of placebo will be administered</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provides informed consent&#xD;
&#xD;
          -  Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain&#xD;
             reaction (PCR) or other commercial or public health assay in any specimen&#xD;
&#xD;
          -  3. Is hospitalized with COVID-19-induced ARD or ARDS (any severity) with a PaO2/FiO2&#xD;
             ≤300. The PaO2/FiO2 may be estimated from pulse oximetry or determined by arterial&#xD;
             blood gas&#xD;
&#xD;
          -  Requires oxygen supplementation at screening&#xD;
&#xD;
          -  Is willing to follow contraception requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current standard of care treatments for COVID-19 appear to be working and the subject&#xD;
             is clinically improving&#xD;
&#xD;
          -  A previous MSC infusion unrelated to this trial&#xD;
&#xD;
          -  Have any of the following medical conditions:&#xD;
&#xD;
               -  Cardio-pulmonary resuscitation within 14 days of randomization&#xD;
&#xD;
               -  Uncontrolled or untreated symptomatic arrhythmias. Exception: Subjects with&#xD;
                  controlled, asymptomatic atrial fibrillation during screening may enroll&#xD;
&#xD;
               -  Myocardial infarction within the last 6 weeks&#xD;
&#xD;
               -  Congestive heart failure (NYHA Grade 3 or 4)&#xD;
&#xD;
               -  Pulmonary hypertension (WHO Class III/IV)&#xD;
&#xD;
               -  Currently receiving extracorporeal life support or membrane oxygenation&#xD;
                  (ECLS/ECMO)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) ≥ 5x upper limit of normal (ULN)&#xD;
&#xD;
               -  Relevant renal impairment (eGFR &lt; 50 mL/min)&#xD;
&#xD;
               -  Any significant medical condition, laboratory abnormality or psychiatric illness&#xD;
                  that in the investigator's opinion would interfere or prevent the subject from&#xD;
                  safely participating in the study&#xD;
&#xD;
          -  Pregnant or breast feeding or planning for either during the study&#xD;
&#xD;
          -  Suspected uncontrolled active bacterial, fungal, viral, or other infection (aside from&#xD;
             infection with COVID-19)&#xD;
&#xD;
          -  History of a splenectomy, lung transplant or lung lobectomy;&#xD;
&#xD;
          -  Concurrent participation in another clinical trial involving therapeutic interventions&#xD;
             (observational study participation is acceptable).&#xD;
&#xD;
          -  Expected survival or time to withdrawal of life-sustaining treatments expected to be &lt;&#xD;
             7 days.&#xD;
&#xD;
          -  Do Not Intubate order;&#xD;
&#xD;
          -  Home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for&#xD;
             continuous positive airway pressure or bi-level positive airway pressure (CPAP/BIPAP)&#xD;
             used solely for sleep-disordered breathing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Royal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sorrento Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mike Royal, MD</last_name>
    <phone>858-203-4100</phone>
    <phone_ext>4146</phone_ext>
    <email>mroyal@sorrentotherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fresno Community Hospital</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rebekah Garcia, CCRP</last_name>
      <phone>559-499-6636</phone>
      <email>rgarcia@fresno.ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christine Mergillano, BS, CCRP</last_name>
      <phone>559-499-6639</phone>
      <email>cmergillano@fresno.ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eyad Almasri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covid-19</keyword>
  <keyword>ARDS</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

